EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›ELA

ELA

Envela Corp

Next earnings Aug 4, 2026 · consensus $0.12 EPS, $60.5M rev

Buy
$27.79
▲ +5.89%
$27.79▲ +370.14%
over 1Y
L $5.42EODHDH $27.79
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.9%
1W+0.9%
1M+3.7%
3M+63.9%
YTD+131.8%
1Y+370.2%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B
Valuation
Overvalued
Filings
Watch
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Buy

Revenue grew 33.6% YoY.

The read

The fundamentals carry the rating, but the price is rich (~23% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.

Envela Corp shows $241M in FY2025 revenue (+33.6% YoY), a 6.1% net margin, and 21.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue——$175M$180M$241M
Gross profit$31.2M$44.8M$41.7M$44.3M$53.9M
Operating income$9.50M$13.9M$8.76M$8.16M$18.1M
Net income$10.0M$15.7M$7.15M$6.76M$14.6M
Diluted EPS$0.37$0.58$0.27$0.26$0.56
Net margin——4.1%3.7%6.1%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$713M
EV / EBITDA35.7
EV / Sales3.0
EV / FCF516.7
P / FCF522.6
PEG (trailing)0.43
Earnings yield2.0%
FCF yield0.2%

Quality & risk

ROIC (est.)18.6%
Free cash flow$1.38M
Total debt$9.92M
Net cash$8.23M
Altman Z-Score19.12 safe
Piotroski F-Score6/9

Capital returns

Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-0.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-06-25
  2. 10-Q Quarterly report2026-05-06
  3. DEF 14A Proxy statement2026-04-27
  4. 8-K Other event2026-04-10
  5. 10-K Annual report2026-03-18
  6. 10-Q Quarterly report2025-11-05
  7. 10-Q Quarterly report2025-08-06
  8. 8-K Officer / director change2025-07-17
  9. 8-K Officer / director change2025-07-01

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-242026-06-25open ↗4Period ending 2026-05-222026-05-22open ↗10-QPeriod ending 2026-03-312026-05-06open ↗DEF 14APeriod ending 2026-06-242026-04-27open ↗8-KPeriod ending 2026-04-092026-04-10open ↗10-KPeriod ending 2025-12-312026-03-18open ↗3Period ending 2026-02-042026-02-05open ↗4Period ending 2025-11-282025-12-01open ↗10-QPeriod ending 2025-09-302025-11-05open ↗4Period ending 2025-08-192025-08-19open ↗S-8Filing2025-08-13open ↗10-QPeriod ending 2025-06-302025-08-06open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueC-
GrowthA+
ProfitabilityB-
Financial healthA-
Momentum—
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$21.28

Overvalued -23% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.56 × (8.5 + 1.5 × 22.0% growth) × 1.10 quality = 38.0× multiple. An estimate, not a price target.

Revenue
$241M
+33.6% YoY
Net margin
6.1%
ROE
21.8%
P/E
49.6

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$241M+33.6%
Net income$14.6M+116.0%
Gross profit$53.9M+21.7%
Operating income$18.1M+122.0%
Diluted EPS$0.56+115.4%
Cash & equivalents$18.2M-11.9%
Total assets$96.0M+23.3%
Total liabilities$29.0M+14.8%
Stockholders' equity$67.1M+27.4%
Gross: 22.4%Op.: 7.5%L/E: 0.43x

Frequently asked

Is Envela Corp (ELA) a buy?
ELA currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 33.6% YoY.
What is ELA's fair value?
A Modified-Graham model based on ELA's SEC fundamentals estimates a fair value of about $21.28. It is an estimate from reported earnings, not a price target.
Is ELA overvalued or undervalued?
Against a Modified-Graham fair-value estimate, ELA currently appears overvalued relative to its SEC-grounded earnings power.
What is Envela Corp's quality score?
ELA scores 73.8235294117647/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000701719, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 7:45:19 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 1 open-market buy · 0 sales

2026-05-22
DeLuca John Garrett
CFO
Buy55.00 @ $23.94$1.32K
2025-11-28
DeLuca John Garrett
CFO
Buy90.00 @ $11.78$1.06K
2025-08-19
DeLuca John Garrett
CFO
Buy280.00 @ $7.09$1.99K
2025-06-04
DeLuca John Garrett
CFO
Buy500.00 @ $5.81$2.90K
2024-12-05
DeLuca John Garrett
CFO
Buy125.00 @ $7.48$935.00
2024-08-22
DeLuca John Garrett
CFO
Buy400.00 @ $5.15$2.06K
2024-05-30
DeLuca John Garrett
CFO
Buy400.00 @ $4.59$1.84K
2024-05-16
DeLuca John Garrett
CFO
Buy225.00 @ $4.60$1.03K

Dividends

Irregular
Yield (TTM)
—
Annual / share
—
Last ex-date
2016-09-12
Last amount
$0.37
ex 2016-09-12$0.37
ex 2016-06-10$0.37
ex 2016-03-10$0.37
ex 2015-12-10$0.37
ex 2015-09-10$0.37
ex 2015-06-10$0.37

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2022-05-04—▼ -5.30%8-K ↗
2019-05-23—▲ 0.00%8-K ↗
2019-04-17—▼ -6.67%8-K ↗
2018-11-21—▲ 0.00%8-K ↗
2018-08-15—▲ 0.00%8-K ↗
2018-05-14—▼ -2.63%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Is Envela (ELA) Outperforming Other Retail-Wholesale Stocks This Year?Bullish
finance.yahoo.com· 2026-04-29
Bet on Winning DuPont Analysis & Pick 5 Top StocksBullish
finance.yahoo.com· 2026-04-09
Has Envela (ELA) Outpaced Other Retail-Wholesale Stocks This Year?Bullish
finance.yahoo.com· 2026-03-26
Hidden Gems for Nervous Investors: 4 Safe Haven Stocks Flying Below the RadarBullish
finance.yahoo.com· 2026-03-10
Exploring 3 Undiscovered Gems In The US MarketBullish
finance.yahoo.com· 2026-02-17
Discovering Undiscovered Gems in the US Market January 2026Bullish
finance.yahoo.com· 2026-01-13

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score74 vs 67
Revenue growth33.6% vs 7.1%
Net margin6.1% vs 10.5%
Return on equity21.8% vs 12.3%
P/E49.6 vs 25.5